Craig Conoscenti, M.D., FCCP, ATSF joined Avalyn Pharma as senior vice president, clinical development in 2023, prior to which he was executive director and therapeutic area head, interstitial lung disease clinical development and medical affairs of Boehringer Ingelheim. Dr. Conoscenti held roles of increasing responsibility within ILD clinical research during his time at Boehringer Ingelheim and was a key contributor to the development and launch of oral nintedanib for idiopathic pulmonary fibrosis (IPF), scleroderma associated ILD (SSc-ILD), and the other progressive fibrosing ILDs (PFILD). Prior to joining Boehringer Ingelheim, Dr. Conoscenti held various titles and senior pulmonary critical care consultant over 17 years at Norwalk Hospital in Norwalk, CT.

Dr. Conoscenti earned a Doctor of Medicine from St George’s University and a Bachelor of Science in Physiology from Fordham University. He completed his residency at Hackensack University Medical Center, where he additionally served one year as Chief Medical Resident. Following this, he completed his Pulmonary Critical Care Fellowship at Norwalk Hospital/Yale University School of Medicine. Dr. Conoscenti is a Fellow of the American Thoracic Society, the American College of Chest Physicians and the European Respiratory Society. He received the Norman S Brady Fellowship where he served sabbatical time at the Brompton Chest Hospital in London.